elmiron® for bladder pain syndrome not recommended in initial assessment by NICE

Consilient Health is extremely disappointed that the initial recommendation from the National Institute for Health and Care Excellence (NICE), detailed in its appraisal consultation document (ACD) released today, is negative for elmiron® (pentosan polysulfate sodium).  elmiron is the only licensed oral medication for bladder pain syndrome (BPS) with glomerulations or Hunner’s lesions (referred to as interstitial cystitis/BPS)1.

Commenting on the NICE recommendation, Mr Jonathan Goddard, Consultant Urological Surgeon, Leicester General Hospital said: “BPS is a chronic condition, challenging to manage and difficult to treat. There is no standard treatment; we often try several treatments before finding one that is suitable for a patient. It’s crucial to have a range of treatments in our armamentarium; elmiron is effective and well-tolerated, and should an available option for appropriate patients.”1.

Susannah Fraser, Communication and Media Manager, Bladder Health UK said: “The intense pelvic pain and unrelenting urgency to pee has a considerable detrimental impact on an individual’s lifestyle, ability to work, emotional health and relationships.  Their quality of life is hugely compromised. elmiron is already licensed and should be available to women and men affected by this debilitating condition.”1.

The Department of Health asked NICE to produce guidance on the use of elmiron for use in the National Health Service (NHS) in England.  An appraisal consultation document has been produced setting out the initial recommendations made by NICE.  This document is not NICE’s final guidance and feedback has been requested by the 1 August 2019, with a second appraisal committee meeting scheduled for the 21 August 2019.1

“Interstitial cystitis/BPS is a rare but excruciating condition, and elmiron is a much needed treatment option. There is a clear clinical need for this medication, and Consilient Health will be working with NICE to ensure that the appropriate patients continue to have access to elmiron” said Luke Crosbie, Consilient Health Executive Vice Chairman.


Code No: UK-ELM-29b

Date of Preparation: July 2019

Angelini Farmaceutica to distribute Benferol® in Spain

Consilient Health is pleased to announce that we have signed a long term, exclusive agreement with Angelini Farmaceutica S.A for them to launch and distribute Benferol® in the Spanish market.

“Spain is an extremely important territory for Benferol® “, commented Executive Vice Chairman Luke Crosbie.  “We are delighted to be partnering with a company as well-respected and successful as Angelini and look forward to a successful launch in Spain later this year”.

Spain is a new territory for the Consilient Health portfolio and it further strengthens our geographic reach within Europe and the Middle East.



Code No: UK/CH/0519/0074

Date of Preparation: May 2019

Agreement signed for elmiron® with bene-Arzneimittel GmbH

Consilient Health are pleased to announce the signing of a long-term, exclusive distribution agreement with bene-Arzneimittel GmbH, a Munich-based pharmaceutical company, to distribute elmiron® in the UK.

The UK deal was signed on 8th May 2018 and, further to that, a distribution agreement was signed on 26th November 2018 for Ireland for elmiron®.

elmiron® allows Consilient Health to expand in to the exciting urology segment and is in line with the company’s strategy of partnering with innovative companies to bring to market medicines that serve a clear unmet clinical need.

Code No: UK/ELM/0419/0026

Date of Preparation: April 2019

Consilient Health welcomes Non-Executive Director, Harald F. Stock PhD

Consilient Health is pleased to announce the appointment of Harald F. Stock PhD as Non-Executive Director of the Company.

Harald has worked in the industry for over 22 years. His extensive experience working with pharmaceuticals, diagnostics and medical devices compliments Consilient Health’s capabilities in a broad range of therapeutic areas.

Harald has worked within a variety of companies, developing and utilising his broad range of expertise. He has worked across Europe, the US, Asia-Pacific and Latin America. Harald has filled previous CEO and Presidential roles in companies including:

  • OvaScience (NADAQ:OVAS), a biotechnology company
  • ArjoHuntleigh AB, a medical equipment company
  • Grünenthal, a privately held, international research-based pharmaceutical company;
  • Chairman and Managing Director at DePoy International, the orthopaedics division of Johnson & Johnson.

Harald has also had various roles with Roche, including SVP in charge of the global Near Patient Testing business. He is currently Non-Executive Director of three other US and European healthcare companies.

Honoured and delighted

Harald states: “I am honoured and delighted to join Consilient Health’s Board. The Company’s unique business model and successful evolution has impressed me, and I am looking forward to working with the Board and Management in shaping the company’s path into an equally successful future.”

Consilient Health welcomes Harald to the Board and looks forward to benefiting from Harald’s extensive international experience and expertise.



Code No: UK/CH/1118/0039

Date of Preparation: April 2019

Consilient Health Limited Announces Board Changes

Consilient Health is pleased to announce the appointment of Mr John Dixon as Non-Executive Director of the Company.

John joined the pharmaceutical industry in 1974 and, from 1982, remained with Boehringer Ingelheim. During that time John is well known for heading up the Global Respiratory Marketing function and for launching BI’s first ever blockbuster “Spiriva” for chronic obstructive pulmonary disease (COPD) with peak sales of €5 billion. John later took up the post of Managing Director in Australia and New Zealand before returning to the UK where he held the position of Managing Director for the UK and Ireland before retiring from BI at the end of 2013.

Commenting on his appointment John said, “I am very pleased to be joining the Consilient Health board and supporting all our efforts to develop and grow the total business. The addition of Innovative Medicines to Consilient Health’s current strong portfolio will strengthen our overall business profile. I am looking forward to working with all the teams to create successful strategies and overcome challenges as we move forward in our commercial development.”

Consilient Health’s board looks forward to benefiting from the wisdom and support of John Dixon to continue to develop its business at this exciting time for the company.

Due to his other commitments, Mr Harry Stratford OBE (who has served as a Non-Executive Director since January 2015) has decided to step down from the Consilient Health board. The board is very grateful to Harry for all his guidance and support over the last three years and wishes him well for the future.



Code No: UK/CH/0419/0068
Date of Preparation: April 2019